5 of Last Week's Biggest Losers

Before you go, we thought you'd like these...
Before you go close icon

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.


Nov. 22

Weekly Loss













Model N 



Source: Barron's.

Let's start with Organovo. After four consecutive weeks of double-digit percentage gains -- capped off by a 52% surge last week alone after providing an upbeat business update -- Organovo proved mortal. There was no negative news to bring the stock lower, but after a torrid run over the past month, it's not a surprise to see it correcting. The 3-D bioprinting star is hoping to generate human tissue that could be used to speed up clinical drug trials. It's still on track to hit the market with a liver toxicity test -- its first commercial product -- next year. As brutal as a 27% drop may seem, it's still trading well above where it was two weeks ago.

Bazaarvoice stumbled after posting quarterly results. The provider of social commerce software offered up uninspiring guidance. It also surprised investors by announcing that its CEO is leaving the company.

Qunar shares went into a descending pattern after the company behind the fast-growing travel platform in China posted its first quarterly results as a public company. The numbers seem solid at first glance. Revenue climbed 58% for the period, and Qunar's guidance calls for growth to accelerate with at least 60% in year-over-year growth for the current quarter. Mobile usage skyrocketed, a metric that's growing more and more important to track these days. However, the market was holding out for more after the stock's successful IPO. 

SolarCity stumbled after an Alabama senator sent a letter to Treasury Secretary Jacob Lew questioning the taxpayer-funded grants the solar-panel installer reportedly was receiving. SolarCity's stock was roaring through most of 2013, as the Elon Musk-fronted company grew popular with its 20-year residential solar energy leases. Its lack of profitability has made it vulnerable after its most recent run.

Model N wasn't a model citizen after the provider of revenue management solutions for the high-tech and medical industries posted quarterly results. The market was initially impressed by its better-than-expected results -- sending the shares initially higher -- but then the focus became its weak guidance on the bottom line. Model N is now projecting a much steeper loss for the fiscal year that started last month. Model N was a hot IPO when it went public at $15.50 earlier this year, but now it has surrendered half of its value.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? If you're tired of watching your stocks creep up year after year at a glacial pace, Motley Fool co-founder David Gardner, founder of the world's No. 1 growth-stock newsletter, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, with you! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains, and click here for instant access to a whole new game plan of stock picks to help power your portfolio.

The article 5 of Last Week's Biggest Losers originally appeared on Fool.com.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends and owns shares of SolarCity. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading